» Articles » PMID: 22798623

Facioscapulohumeral Muscular Dystrophy Family Studies of DUX4 Expression: Evidence for Disease Modifiers and a Quantitative Model of Pathogenesis

Abstract

Facioscapulohumeral muscular dystrophy (FSHD), the most prevalent myopathy afflicting both children and adults, is predominantly associated with contractions in the 4q35-localized macrosatellite D4Z4 repeat array. Recent studies have proposed that FSHD pathology is caused by the misexpression of the DUX4 (double homeobox 4) gene resulting in production of a pathogenic protein, DUX4-FL, which has been detected in FSHD, but not in unaffected control myogenic cells and muscle tissue. Here, we report the analysis of DUX4 mRNA and protein expression in a much larger collection of myogenic cells and muscle biopsies derived from biceps and deltoid muscles of FSHD affected subjects and their unaffected first-degree relatives. We confirmed that stable DUX4-fl mRNA and protein were expressed in myogenic cells and muscle tissues derived from FSHD affected subjects, including several genetically diagnosed adult FSHD subjects yet to show clinical manifestations of the disease in the assayed muscles. In addition, we report DUX4-fl mRNA and protein expression in muscle biopsies and myogenic cells from genetically unaffected relatives of the FSHD subjects, although at a significantly lower frequency. These results establish that DUX4-fl expression per se is not sufficient for FSHD muscle pathology and indicate that quantitative modifiers of DUX4-fl expression and/or function and family genetic background are determinants of FSHD muscle disease progression.

Citing Articles

Temporal variation in p38-mediated regulation of DUX4 in facioscapulohumeral muscular dystrophy.

Vangipurapu R, Oliva J, Fox A, Sverdrup F Sci Rep. 2024; 14(1):26437.

PMID: 39488616 PMC: 11531483. DOI: 10.1038/s41598-024-77911-8.


SMCHD1 activates the expression of genes required for the expansion of human myoblasts.

Wong M, Hachmer S, Gardner E, Runfola V, Arezza E, Megeney L Nucleic Acids Res. 2024; 52(16):9450-9462.

PMID: 38994563 PMC: 11381350. DOI: 10.1093/nar/gkae600.


French National Protocol for diagnosis and care of facioscapulohumeral muscular dystrophy (FSHD).

Attarian S, Beloribi-Djefaflia S, Bernard R, Nguyen K, Cances C, Gavazza C J Neurol. 2024; 271(9):5778-5803.

PMID: 38955828 DOI: 10.1007/s00415-024-12538-3.


Single-cell spatial transcriptomics reveals a dystrophic trajectory following a developmental bifurcation of myoblast cell fates in facioscapulohumeral muscular dystrophy.

Chen L, Kong X, Johnston K, Mortazavi A, Holmes T, Tan Z Genome Res. 2024; 34(5):665-679.

PMID: 38777608 PMC: 11216401. DOI: 10.1101/gr.278717.123.


Comprehensive genetic analysis of facioscapulohumeral muscular dystrophy by Nanopore long-read whole-genome sequencing.

Huang M, Zhang Q, Jiao J, Shi J, Xu Y, Zhang C J Transl Med. 2024; 22(1):451.

PMID: 38741136 PMC: 11092085. DOI: 10.1186/s12967-024-05259-8.


References
1.
Tawil R . Facioscapulohumeral muscular dystrophy. Neurotherapeutics. 2008; 5(4):601-6. PMC: 2628543. DOI: 10.1016/j.nurt.2008.07.005. View

2.
de Greef J, Lemmers R, Camano P, Day J, Sacconi S, Dunand M . Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology. 2010; 75(17):1548-54. PMC: 2974464. DOI: 10.1212/WNL.0b013e3181f96175. View

3.
Lemmers R, van der Vliet P, Klooster R, Sacconi S, Camano P, Dauwerse J . A unifying genetic model for facioscapulohumeral muscular dystrophy. Science. 2010; 329(5999):1650-3. PMC: 4677822. DOI: 10.1126/science.1189044. View

4.
van der Maarel S, Tawil R, Tapscott S . Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. Trends Mol Med. 2011; 17(5):252-8. PMC: 3092836. DOI: 10.1016/j.molmed.2011.01.001. View

5.
Geng L, Yao Z, Snider L, Fong A, Cech J, Young J . DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev Cell. 2012; 22(1):38-51. PMC: 3264808. DOI: 10.1016/j.devcel.2011.11.013. View